Cargando…
Biopsy vs. extensive resection for first recurrence of glioblastoma: is a prospective clinical trial warranted?
BACKGROUND: Glioblastoma is an aggressive and almost universally fatal tumor. The prognosis at the time of recurrence has generally been poor, with overall survival typically in the range of 4–40 weeks. The merits of surgical resection (vs. open biopsy, to confirm recurrence via histology) in additi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560929/ https://www.ncbi.nlm.nih.gov/pubmed/26341541 http://dx.doi.org/10.1186/s13104-015-1386-3 |